Taking on the Biggest Killer Takes the Best
In 2012 the World Health Organization ranked ischemic heart disease as the leading cause of death worldwide. Stroke, diabetes mellitus, and hypertensive heart disease also made the top ten list of killer diseases. There is a growing need for new treatments in cardiovascular and metabolic disease (CVMD), yet translational research is often not as fruitful as it should be, with drug development programs relying on poorly predictive rodent models. Non-human primate (NHP) models have the advantage of being much more similar to humans, from their genetics and biochemistry to their physiological and metabolic systems. This increases the predictive power of NHP models, and makes them highly reliable for preclinical work in CVMD disease areas such as diabetes, cardiovascular disease, and hypertension. Partnering with a company who has expert knowledge of NHP models and their uses, can drive forward your translational research and potentially increase your preclinical to clinical trial success rate.
Research into new treatments for CVMD can often be limited by a lack of clinically relevant models showing the same characteristics, development, and comorbidities as the human condition. Large biological differences between rodent models and human disease can result in successful preclinical therapies being spectacular clinical failures. NHP models are more genetically and physiologically similar to humans, yet are sometimes overlooked in translational research due to the complexity of the models, and the training and expertise required to use them.
Crown Bioscience is at the forefront of NHP diabetic research, and has the world’s largest collection of well characterized, naturally diabetic cynomolgus and rhesus monkeys. NHP diabetes models mirror every aspect of the human disease including disease progression, obesity, and complications such as nephropathy and dyslipidemia. This makes spontaneous NHP diabetic models by far the most predictive animal model system in diabetes research. As many next generation antidiabetic agents target disease complications rather than blood glucose control, NHP models are an invaluable resource for understanding efficacy, PK/PD relationship, biomarkers, and possible adverse effects before moving on to successful human clinical trials.
The similarities between NHPs and humans also make NHP models the best suited for other CVMD research areas. These similarities include platelet function, coagulation, fibrinolysis, thrombus formation and dissolution, plasma lipoprotein level, and atherosclerotic plaque development, calcification, and mineralization. NHP models are therefore excellent tools for investigating human cardiovascular pathology and for evaluating therapeutic interventions such as novel thrombotic agents and arteriovenous vascular grafts. These similarities also result in NHP models being extremely useful for research into high blood pressure and research areas such as how hypertension affects atherosclerosis development. There is also some immunological overlap between NHP models and humans which may allow the use of available human assays in your NHP research, if required. Using animal models with such a close correlation to human disease should result in generating the most reliable preclinical data available to inform on moving forward to clinical trials.
Crown Bioscience understands the need to reduce attrition rates in CVMD research through the use of the most clinically relevant models possible. We are world leaders in our development and characterization of naturally diabetic NHP models, and have a wealth of experience throughout NHP use in the CVMD field.
Contact us as today at email@example.com to talk to our experts about how NHP models can drive forward your translational research.